## How you can help

With billions of dollars invested, tomorrow's advances in the fight against cancer can only come from one sourcetoday's research. The greatest advances in cancer research are just over the horizon. New discoveries are being made every day and the American Cancer Society continues to make them possible. But, we need your help and support to continue the progress.

Aside from the U.S. government, we fund the largest percentage of cancer researchers at the start of their careers, when they might not otherwise receive funding to get new ideas off the ground. We have proven results, with 46 of our former grantees having gone on to win the Nobel Prize - a testament to our ability to identify the best and brightest ideas.
In any given year there are between $\$ 450$ million and $\$ 500$ million in multi-year American Cancer Society research grants in effect. Indiana and Michigan, home to some of the most prestigious medical and research facilities in the world, receive a significant portion of the Society's annual research expenditure.
Unfortunately, our organization can only fund a small percentage of research grants each year. Any one of the approved applications that go unfunded could potentially be the research that results in a cancer breakthrough The American Cancer Society needs your continued support to help researchers find a cure.
Call us at 1-800-227-2345 to find out how you can contribute to the fight, either as a volunteer or a donor

## Did you know:

When the American Cancer Society began its research program in 1946, only 25 percent of cancer patients were alive five years after diagnosis. Today, about 67 percent live longer than five years. Against the odds, the Society has turned cancer from a taboo topic into a rallying cry for change. In total, we've helped avert more than 650,000 cancer deaths just since the early 1990s - creating about 350 more birthdays each and every day.


## The Promise of Cancer Research

Helping to Save Lives and Create a World with Less Cancer and More Birthdays


## The search for a cure

The American Cancer Society is internationally recognized as a leader in cancer research. We have a rich history of progress, having launched the nation's first cancer research initiative in 1946 . Since then more than $\$ 3.6$ billion has been invested in cancer research, making the American Cancer Society the largest private source of cancer research dollars in the United States today.

In the Great Lakes Division of the American Cancer Society, we are proud to support our Indiana and Michigan research institutions where scientists work tirelessly to understand the many mysteries of cancer. This includes funding projects that expand scientific knowledge to improve treatments and help us find better ways to identify cancer risk, as well as projects that study people, behaviors and populations to help us understand how to prevent the disease and detect it early. Research is an important component of our mission to help people Stay Well, Get Well, Find Cures, and Fight Back.

And our efforts don't stop with our own research program. As the largest voluntary health organization in the nation today, we use our grass roots army of volunteers and trained advocates-both locally and nationally-to push for badly needed growth in private and government cancer research funding


We save lives and create more birthdays by helping you stay well, helping you get well,
by finding cures, and by fighting back.

## Science at Work in the Great Lakes Division, Inc.

To date, your American Cancer Society has spent over $\$ 3.6$ billion on cancer research and training. Currently, the American Cancer Society is funding nearly $\$ 470$ million in cancer research grants, with nearly $\$ 21$ million* at work at eight research facilities in Indiana and Michigan. As the nation's largest private and not-for-profit investor in cancer research and training, the American Cancer Society pays special attention to young investigators with breakthrough projects to both advance knowledge of the disease and promote a new generation of scientists who can sustain the quest for a cure well into the future.

## Current Research Grants in Indiana and Michigan

| Researcher and Location | Subject Matter | Grant Dates | Grant Amount |
| :---: | :---: | :---: | :---: |
| Rebecca Allan-Gibbs, MSN Wayne State University | Determining Risk Factors Among Hospitalized Cancer Patients | 7/1/ 2010-6/30/2013 | \$15,000 |
| Gerold Bepler, MD, PhD Karmanos Cancer Institute | Institutional Research Grant | 1/1/2011-12/31/2013 | \$360,000 |
| Grace Y. Chen, PhD University of Michigan | Role of Commensals and Innate Immunity in Colitis-Associated Colon | 1/1/2011-12/31/2014 | \$720,000 |
| Mark Chiang, MD, PhD University of Michigan | Targetting NOTCH and TLXI in T-cell Acute Lymphoblastic Leukemia/Lymphoma | 7/1/2011-6/30/2015 | \$720,000 |
| Arul M. Chinnaiyan, MD, PhD University of Michigan | Oncoseq, A Bioinformatics Platform for Nextgen Sequencing in Oncology | 7/1/2009-6/30/2014 | \$400,000 |
| Tomasz Cierpicki, PhD University of Michigan | Menin as an Oncogenic Co-Factor in MLL Leukemias | 1/1/2011-12/31/2014 | \$720,000 |
| Yali Dou, PhD University of Michigan | The Function and Regulation of Histone Acetyltransferase MOF | 7/1/2010-6/30/2014 | \$720,000 |
| James L. Ferrara, MD University of Michigan | Novel Strategies to Treat Graft Versus Host Disease | 7/1/2008-6/30/2013 | \$400,000 |
| William Hawse, PhD University of Notre Dame | Molecular Flexibility in T Cell Receptor Specificity and Crossreactivity | 7/1/2011-6/30/2014 | \$150,000 |
| Samantha Hendren, MD, MPH University of Michigan | Improving Rectal Cancer Surgery through Regional Collaboration | 7/1/2012-6/30/2017 | \$728,000 |
| Patrick Hu, MD, PhD University of Michigan | EAK-7, a Novel Regulator of FoxO Tumor Suppressors | 7/1/2010-6/30/2014 | \$720,000 |
| Mircea Ivan, MD, PhD Indiana University, Indianapolis | Role of miR-210 in the Hypoxia Response and Tumorigenesis | 7/1/2009-6/30/2013 | \$720,000 |
| Bruce L. Jacobs, MD University of Michigan | The Adoption of Intensity-Modulated Radiation Therapy in Prostate Cancer | 1/1/2012-12/31/2012 | \$48,000 |
| Reshma Jagsi, MD, DPhil University of Michigan | Experiences and Outcomes in a Randomized Breast Radiation Technology Trial | 7/1/2009-6/30/2013 | \$580,000 |
| Jae-Wook Jeong, PhD Michigan State University | Understanding the Progression of Endometrial Cancer | 1/1/2012-12/31/2015 | \$720,000 |
| Mark R. Kelley, PD Indiana University, Indianapolis | Institutional Research Grant | 1/1/2009-12/31/2012 | \$360,000 |
| Venkateshwar Keshamouni, PhD University of Michigan | Targeting TGF-beta-mediated Tumor-stromal Interactions in Lung Cancer | 1/1/2009-12/31/2012 | \$720,000 |
| Andrea Manors, BSN Indiana University, Indianapolis | Graduate Scholarship in Cancer Nursing | 7/1/2011-6/30/2013 | \$20,000 |
| Daniela E. Matei, MD Indiana University, Indianapolis | Targeting the Transglutaminase-Finbronectin Interaction in Ovarian Cancer | 1/1/2010-12/31/2013 | \$720,000 |
| Susan M. Mendrysa, PhD Purdue University | Role of MDM2 in Cerebellar Development and Medulloblastoma | 1/1/2012-12/31/2015 | \$720,000 |
| Samy Meroueh, PhD Indiana University, Indianapolis | Docking uPAR for Selective Targeting of Cancer Metastasis | 1/1/2012-12/31/2015 | \$720,000 |
| Melissa Millerick-May, PhD Michigan State University | Exposure Reconstruction in Three Unique Cohorts | 1/1/2011-12/31/2015 | \$671,000 |
| Arden M. Morris, MD, MPH University of Michigan | Patient and Provider Influences on disparities in Colorectal Cancer Care | 7/1/2011-6/30/2015 | \$720,000 |
| Patrick J. O'Brien, PhD Universty of Michigan | Novel Roles of Base Excision Repair in Mutagenesis | 7/1/2011-6/30/2015 | \$720,000 |


| Researcher and Location | Subject Matter | Grant Dates | Grant Amount |
| :---: | :---: | :---: | :---: |
| Mary O'Riordan, PhD University of Michigan | Regulation of AQP1 and Its Role in the Cellular Innate Immune Response | 1/1/2008-12/31/2012 | \$697,000 |
| Sela Panapasa University of Michigan | Understanding Cancer Disparities Among U.S. Pacific Islanders | 1/1/2012-12/31/2014 | \$438,000 |
| Kenneth Pienta, MD University of Michigan | Inhibition of Monocyte Chemoattractant Protein-1 to Treat Prostate Cancer | 7/1/2008-6/30/2013 | \$400,000 |
| Kevin L. Rand, PhD Indiana University, Indianapolis | Goal-Related Thoughts and End-of-Life Decisions in Advanced Cancer Patients | 1/1/2010-12/31/2012 | \$330,000 |
| Timothy L. Ratliff, PhD Purdue University | Institutional Research Grant | 1/1/2011-12/31/2013 | \$180,000 |
| Sameek Roychowdhury, PhD, MD University of Michigan | Individualized Therapies for Genomic Targets: A Personalized Oncology Pilot | 7/1/2012-6/30/2017 | \$729,000 |
| Florian Schroeck, MD University of Michigan | Impact of Technology on the Quantity and Quality of Prostate Cancer Care | 7/1/2012-6/30/2013 | \$48,000 |
| Peter H. Schwartz, PhD, MD Indiana University, Indianapolis | Giving Patients Quantitative Information about Colorectal Cancer Screening Tests | 7/1/2010-6/30/2013 | \$300,000 |
| Vahakn B. Shahinian, MD University of Michigan | Influence of Reimbursement on Androgen Deprivation Use for Prostate Cancer | 1/1/2010-12/31/2012 | \$534,000 |
| Hayley S. Thompson, PhD Karmanos Cancer Institute | Improving Post-Treatment Resources for Latina Breast Cancer Survivors | 7/1/2012-6/30/2017 | \$1,271,000 |
| Yanzhuang Wang, PhD University of Michigan | Structure and Function of the Golgi Stacks During the Cell Cycle | 7/1/2009-6/30/2013 | \$720,000 |
| Daniela Wittmann, MSW Michigan State University | Couples' Sexual Recovery After Prostatectomy and the Role of the Partner | 7/1/2012-6/30/2014 | \$40,000 |
| Andrew Zelhof, PhD Indiana University, Bloomington | Creating as Extracellular Matrix: The Regulation of Spacemaker and Prominin | 1/1/2010-12/31/2013 | \$657,000 |
| Yi Zhang, MD, PhD University of Michigan | Regulation of T Cell Stemness by Ezh2 | 7/1/2010-6/30/2014 | \$720,000 |
| Wuqiang Zhu, PhD Indiana University, Indianapolis | Molecular Dissection of Acute vs. Chronic DOX-induced Cardiotoxicity | 7/1/2011-6/30/2013 | \$102,000 |
| *Grants in effect as of July 2012 | Michigan | Indiana Grant T | \$20,258,000 |

## Current Grants by the Michigan Cancer Research Fund

Special grants made possible by the generous support of the Michigan Cancer Research Fund, a group of Michigan-based volunteers dedicated to supporting peer-reviewed research of the American Cancer Society (mcrf.org).

| Researcher and Location | Subject Matter | Grant Dates | Grant Amount |
| :---: | :---: | :---: | :---: |
| Kristen Admiraal, MSW Michigan State University (MCRF 2012 Fellow) | Quality of Life Outcomes Among Older Adults with Colorectal Cancer | 7/1/2012-6/30/2014 | \$40,000 |
| David DeGraff, PhD Vanderbilt University Medical Center (MCRF 2009 Fellow) | Role of Novel Foxa1 Binding Partners in Androgen Regulated Prostate Cancer | 10/1/2009-9/30/2012 | \$150,000 |
| Kurt Januszyk, PhD Sloan-Kettering Institute for Research (MCRF 2010 Fellow) | Investigations into How the Exosome Recognizes and Degrades RNA | 7/1/2010-6/30/2013 | \$150,000 |
| Amanda Solem, PhD Wayne State University (MCRF 2012 Fellow) | Single-molecule Study of the Spliceome | 7/1/2012-6/30/2014 | \$98,000 |
| Aaron R. Van Dyke, PhD University of Michigan (MCRF 2011 Fellow) | Modulating Androgen Receptor with Bifunctional Recruiters | 11/1/2010-10/31/2013 | \$150,000 |

## MCRF

